Gonçalo Castelo-Branco Group
Our research group is interested in the molecular mechanisms defining the epigenetic state of cells of the oligodendrocyte lineage.
We are focused on how interplay between transcription factors, non-coding RNAs and chromatin modifying enzymes contribute to the transition between epigenetic states within the oligodendrocyte lineage, with the aim to design epigenetic based-therapies to induce regeneration (remyelination) in demyelinating diseases, such as multiple sclerosis.
Chan Zuckerberg Initiative grant to Gonçalo Castelo-Branco
Chan Zuckerberg Initiative grant to Gonçalo Castelo-Branco
Gonçalo Castelo-Branco is leading one of 38 projects that received a Chan Zuckerberg Initiative Seed Networks for the Human Cell Atlas grant. The project will investigate how oligodendrocytes can be different in the human brain and spinal cord.
Protein composition changes stimulate brain development and neuronal communication
Protein composition changes stimulate brain development and neuronal communication
Castelo-Branco group shows that the enzyme PAD2, which can alter protein composition by a process called citrullination, plays an important role in brain development and neuronal communication.
New insights about the role of myelin-producing cells in MS
New insights about the role of myelin-producing cells in MS
Subpopulations of oligodendrocytes, myelin-producing cells in the brain that are targeted by the immune system in multiple sclerosis (MS), are altered in MS and might therefore have additional roles in the disease than previously described. The results are published in Nature, in a study led by the Goncalo Castelo-Branco Lab and researchers at the University of Edinburgh in the UK.
New clues to the origin and progression of multiple sclerosis
New clues to the origin and progression of multiple sclerosis
Mapping of a certain group of cells, known as oligodendrocytes, in the central nervous system of a mouse model of multiple sclerosis (MS), shows that they might have a significant role in the development of the disease. The discovery can lead to new therapies targeted at other areas than just the immune system. The results are published in Nature Medicine.